BY 963

Drug Profile

BY 963

Alternative Names: BY-963; SonoRx

Latest Information Update: 13 Feb 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ImaRx Therapeutics
  • Developer ALTANA Group; Bracco
  • Class Contrast media; Phosphatidylcholines
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Gastrointestinal disorders

Most Recent Events

  • 30 Apr 2002 Discontinued - Phase-III for Gastrointestinal disorders (diagnosis) in Central Europe (PO)
  • 30 Apr 2002 Discontinued - Phase-III for Gastrointestinal disorders (diagnosis) in Germany (PO)
  • 16 Nov 1999 ImaRx Pharmaceutical has been acquired by DuPont
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top